Evidence map›Paper›PMID 30683717›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Cells exhibiting strong

Jie-Yu Liu, George P Souroullas, Brian O Diekman, Janakiraman Krishnamurthy, Brandon M Hall, Jessica A Sorrentino, Joel S Parker, Garrett A Sessions, Andrei V Gudkov, Norman E Sharpless

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 298 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Response to Kawamoto et al.EMBO reports · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. p16Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  19. Article
  20. Review

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jie-Yu LiuCurriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine, Chapel Hill, NC 27599.ORCID 0000-0002-0718-6640
George P SouroullasDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Brian O DiekmanThe Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599.
Janakiraman KrishnamurthyThe Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599.
Brandon M HallResearch Division, Everon Biosciences, Inc., Buffalo, NY 14203.
Jessica A SorrentinoThe Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599.
Joel S ParkerThe Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599.
Garrett A SessionsThurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599.
Andrei V GudkovResearch Division, Everon Biosciences, Inc., Buffalo, NY 14203.
Norman E SharplessCurriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine, Chapel Hill, NC 27599; norman.sharpless@nih.gov.ORCID 0000-0001-7078-9455
University of North Carolina at Chapel Hill · USAbcombi Biosciences (United States) · USRoswell Park Comprehensive Cancer Center · USWashington University in St. Louis · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
The Role of p16INK4 in Mammalian AgingR01AG024379 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HE, SHENGHUI · 2004 to 2019
$4.6M
In vivo murine models of metastasis for therapeutic testingR01CA163896 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHARPLESS, NORMAN E, WONG, KWOK KIN · 2012 to 2016
$2.0M
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA163896NIA NIH HHS R01 AG024379NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

The activation of cellular senescence throughout the lifespan promotes tumor suppression, whereas the persistence of senescent cells contributes to aspects of aging. This theory has been limited, however, by an inability to identify and isolate individual senescent cells within an intact organism. Toward that end, we generated a murine reporter strain by "knocking-in" a fluorochrome, tandem-dimer Tomato (tdTom), into exon 1α of the

Indexed as

Promoter Regions, GeneticAnimalsbeta-GalactosidaseCell ProliferationCellular SenescenceCyclin-Dependent Kinase Inhibitor p16Enzyme ActivationFibroblastsHalf-LifeHumansMicePhenotypeRNA, Messengerbeta-GalactosidaseCyclin-Dependent Kinase Inhibitor p16RNA, Messengeragingcdkn2asenescence

Identifiers

PMID30683717
PMCPMC6377452
OpenAlexW2914786282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.